6505--Perphenazine Tablets (VA-25-00037353)

The Department of Veterans Affairs National Acquisition Center is soliciting proposals for Perphenazine Tablets across four different strengths (2mg, 4mg, 8mg, and 16mg), packaged in 100-tablet bottles. This five-year requirements contract will serve multiple federal agencies including VA, DoD, Bureau of Prisons, and Indian Health Service. Potential suppliers must provide an 11-digit NDC number unique to their company, submit a Letter of Commitment from the manufacturer, and maintain FDA current Good Manufacturing Practices (cGMP) compliance. Offerors are required to submit pricing for a base year and four subsequent option years, with unit prices not exceeding two decimal places and including a 0.5% Cost Recovery Fee. The original solicitation closing date of April 24, 2025, at 2:30 PM CDT was extended to May 1, 2025, at the same time, as noted in the Standard Form 30 Amendment.

The solicitation is set aside for small businesses with a size standard of 1,300 employees, and the total estimated annual usage is approximately 13,409 bottles across all tablet strengths. The contract will be distributed through Pharmaceutical Prime Vendor programs, with McKesson Corporation listed as a potential distribution partner. Estimated annual usage varies by strength, ranging from 1,137 to 5,191 bottles per strength across participating agencies. The anticipated contract effective date is August 19, 2025, with a single aggregate award planned for all line items. Suppliers must also demonstrate compliance with the Drug Supply Chain Security Act (DSCSA) requirements and maintain appropriate FDA approvals. The pharmaceutical preparation will be manufactured under NAICS category 325412 and falls under PSC category 6505 for Drugs and Biologicals.